PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
Molecules · 26.01.2023 · 28 (3) · 1217
DOI: 10.3390/molecules28031217 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 26.01.2023. Verfasst von Xuelian Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 172 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Nature Science Foundation of China, National Nature Science Foundation of China Youth Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
The epigenetic regulation of gene functions has been proven to be strongly associated with the development and progression of cancer. Reprogramming the cancer epigenome landscape is one of the most promising target therapies in both treatments and in reversing drug resistance. Proteolytic targeted chimeras (PROTACs) are an emerging therapeutic modality for selective degradation via the native ubiquitin-proteasome system. Rapid advances in PROTACs have facilitated the exploration of targeting epigenetic proteins, a lot of PROTAC degraders have already been designed in the field of epigenetic cancer therapy, and PROTACs targeting epigenetic proteins can better exploit target druggability and improve the mechanistic understanding of the epigenetic regulation of cancer. Thus, this review focuses on the progress made in the development of PROTAC degraders and PROTAC drugs targeting epigenetics in cancer and discusses challenges and future opportunities for the field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
- Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan 430071, China.
- Hubei Cancer Clinical Study Center, Wuhan 430071, China.
- Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Förderung
- National Nature Science Foundation of China
- National Nature Science Foundation of China Youth Project
- National Natural Science Foundation of China
- National Natural Science Foundation of China Youth Project
Zitieren
APA
Liu, X., Wang, A., Shi, Y., Dai, M., Liu, M., & Cai, H. B. (2023). PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities. Molecules, 28(3), 1217. https://doi.org/10.3390/molecules28031217
Vancouver
Liu X, Wang A, Shi Y, Dai M, Liu M, Cai HB. PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities. Molecules. 2023;28(3):1217. doi:10.3390/molecules28031217
BibTeX
@article{Liu2023,
author = {Liu, Xuelian and Wang, Anjin and Shi, Yuying and Dai, Mengyuan and Liu, Miao and Cai, Hong-Bing},
title = {PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities},
journal = {Molecules},
year = {2023},
volume = {28},
number = {3},
pages = {1217},
doi = {10.3390/molecules28031217}
}
EUVIMED